BiomX Inc. (PHGE) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: positive trial results and strong interest in BX004, but with significant regulatory and market risks. Financial metrics show decreased losses and cash usage, but the net cash position is declining. The Q&A highlights enthusiasm for BX004 but also reveals management's reluctance to provide specific timelines, suggesting uncertainty. Without clear guidance or new partnerships, and considering the absence of a market cap, the stock price is likely to remain stable, leading to a neutral sentiment.
Key Financial Performance
Cash balance and restricted cash $15.2 million as of June 30, 2025, compared to $18 million as of December 31, 2024. The decrease was primarily due to net cash used in operating activities.
Research and development expenses $5 million for Q2 2025 compared to $6.9 million for Q2 2024, a decrease primarily driven by reduced salary expenses from workforce reductions, lower rent expenses following 2024 right-of-use asset impairment accounting, and increased grant funding. This was partially offset by higher expenses from initiating the Phase IIb clinical trial for BX004.
General and administrative expenses $2.4 million for Q2 2025 compared to $2.8 million for Q2 2024, a decrease primarily attributed to a reduction in legal and other professional service fees, partially offset by increased share-based compensation expenses.
Net loss $6 million for Q2 2025 compared to income of $4.5 million for Q2 2024. The decrease was mainly due to the change in the fair value of warrants issued as part of the company's March 2024 financing.
Net cash used in operating activities $14.8 million for the six months ended June 30, 2025, compared to $22.6 million for the same period in 2024.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
BX004 Phase IIb trial: Initiated patient dosing for cystic fibrosis patients, with top-line results expected in Q1 2026. The trial is randomized, double-blind, placebo-controlled, and measures multiple efficacy endpoints.
BX211 Phase II results: Reported positive results in March 2025, showing safety, tolerability, and significant reduction in ulcer size for diabetic foot osteomyelitis patients. Planning for a registrational study pending FDA feedback.
Scientific validation: Published data in Nature Communications showcasing antimicrobial efficacy of BX004 and innovative data analysis methods, enhancing credibility in the scientific community.
Financial position: Cash balance of $15.2M as of June 30, 2025, sufficient to fund operations into Q1 2026. Reduced R&D and administrative expenses compared to 2024.
Operational efficiencies: Achieved cost reductions through workforce reductions, lower rent expenses, and increased grant funding.
FDA feedback and collaboration: Awaiting FDA feedback on real-world evidence approach for BX004 and engaging with the U.S. Defense Health Agency for BX211 development.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Cash and Financial Sustainability: The company has a cash balance of $15.2 million as of June 30, 2025, which is projected to fund operations only until the first quarter of 2026. This limited cash runway poses a risk to the company's ability to sustain operations and execute its strategic objectives if additional funding is not secured.
Clinical Trial Execution: The success of the BX004 and BX211 programs is contingent on the timely execution of clinical trials. Delays in patient enrollment, regulatory feedback, or trial execution could impact the company's ability to meet its milestones and timelines.
Regulatory Feedback and Approval: The company is awaiting feedback from the FDA regarding the use of real-world evidence for BX004. Any unfavorable feedback or delays in regulatory approval could hinder the progress of the BX004 program and its market entry.
Market and Competitive Risks: The BX211 program targets diabetic foot osteomyelitis (DFO), a challenging indication with no approved therapeutics in over 20 years. While this represents an opportunity, it also underscores the difficulty of achieving regulatory approval and market acceptance.
Operational Cost Management: The company has reduced research and development expenses and general administrative costs, but these reductions may impact operational efficiency and the ability to scale effectively.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
BX004 Phase IIb Clinical Trial: The company has successfully initiated patient dosing in the Phase IIb clinical trial of BX004 for cystic fibrosis patients. Top-line results are expected in the first quarter of 2026. The trial is designed to measure multiple efficacy endpoints, including reduction in bacterial burden, improvement in lung function, and enhanced quality of life.
BX211 Program: The company is planning a registrational study for BX211, pending feedback from the FDA. Discussions with the U.S. Defense Health Agency are ongoing to support the development of this program.
FDA Feedback on Real-World Evidence: BiomX expects to receive feedback from the U.S. FDA regarding the potential use of real-world evidence linking material reduction to clinical outcomes during the second half of 2025.
Cash Runway: The company estimates that its cash, cash equivalents, and restricted cash are sufficient to fund operations into the first quarter of 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Have you seen a relative inflection with regard to site and physician interest in the 004 study based on positive clinical data?
A:Yes, there has been significant excitement and interest from sites, patients, and physicians. This is attributed to prior data, safety comfort, and publications in highly acclaimed journals. There is also strategic interest, and the field appears to be at an inflection point.
Q:What is your wish list for a registrational study for 211, and how does it link with discussions with the Defense Health Agency?
A:The data set for 211 is very promising, showing a 40% reduction in a tough indication. The path forward includes diabetic foot osteo and diabetic foot infection, with endpoints around infection resolution. The Defense Health Agency supports programs with private market use, and they have provided almost $40 million in non-dilutive funding. Discussions with regulatory agencies are ongoing, and more data is being gathered.
Q:What is the utility and benefit of the real-world evidence you are providing to the FDA for 004?
A:Real-world evidence could potentially accelerate approval based on microbiology. Historical data shows that bacterial infections lead to worse outcomes. The company is gathering data from registries, literature, and KOL recommendations to build a case for alignment with the FDA. The goal is to hasten the approval process, though discussions are still early.
Q:What is the enrollment status for the 004 study?
A:Enrollment is progressing well, with significant excitement from sites, patients, and caretakers. The study is on track to have data ready in the first quarter.
Q:Have you prepared materials for discussions with the FDA regarding real-world data for 004?
A:Yes, the company has convened KOL panels, gathered real-world evidence from registries, conducted literature analysis, and surveyed care territories. This data will support discussions with the FDA, though alignment is still ongoing.
Q:What is the general framework for the 211 registrational study, and when will discussions with the FDA occur?
A:The framework includes endpoints like infection resolution for diabetic foot infections and longer-term infection resolution for diabetic foot osteo, including MRI and X-ray evaluations. Discussions with the FDA are planned for the second half of the year, and the company is preparing to solidify its understanding with guidance documents and expert input.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the enrollment numbers for the 004 study, stating only that it is progressing well. Additionally, they did not provide a clear timeline for when discussions with the FDA regarding real-world data for 004 would occur, emphasizing that alignment is still ongoing.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Agency financer
Authority Phase
BX General
BX IIa
BX event
BX improvement
BX initiation
BX program
BX study
BX trial
II result
IIb trial
Phase II
Phase IIb
area
decrease
discussion
enthusiasm
feedback FDA
initiation patient
momentum milestone
need patient
opinion leader
parallel
platform progress
publication
reduction
result BX
strength
therapy platform
trial BX
trial efficacy
ulcer death
validation phage
PHGE Transcript
BiomX Inc. (PHGE) Q3 2025 Earnings Call Transcript
Unknown11-12
The earnings call highlighted significant financial challenges, including a substantial net loss and a declining cash balance. Despite some positive developments, such as potential DHA support and FDA feedback, the financial health concerns and lack of clear guidance on critical issues, like the nebulizer hold, overshadowed these positives. The Q&A revealed management's vague responses, especially regarding the Phase III study for BX004, contributing to uncertainty. These factors, combined with the operational reductions and financial risks, suggest a likely negative impact on the stock price.
BiomX Inc. (PHGE) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call presents a mixed picture: positive trial results and strong interest in BX004, but with significant regulatory and market risks. Financial metrics show decreased losses and cash usage, but the net cash position is declining. The Q&A highlights enthusiasm for BX004 but also reveals management's reluctance to provide specific timelines, suggesting uncertainty. Without clear guidance or new partnerships, and considering the absence of a market cap, the stock price is likely to remain stable, leading to a neutral sentiment.
BiomX Inc. (AMEX:PHGE) Q1 2025 Earnings Call Transcript
Unknown5-17
The earnings call indicates positive developments, such as ongoing clinical trials and financing to support operations until 2026. However, there are significant risks, including regulatory uncertainties and financial sufficiency concerns. The Q&A section highlighted unclear responses from management, contributing to uncertainty. Although the company is addressing unmet needs, the lack of immediate catalysts and the absence of a market cap suggest a neutral stock price movement in the short term.
BiomX Inc. (PHGE) Q1 2025 Earnings Conference Call Transcript
Unknown5-15
The earnings call presents a mixed picture. Financially, the company has decreased its net loss and improved cash management, but there are ongoing financial challenges and reliance on external funding. Regulatory risks and competitive pressures in the DFO market remain significant concerns. The Q&A reveals some uncertainty in regulatory interactions and study designs, which could affect investor sentiment. However, the $12 million financing and non-diluted funding from the U.S. Defense Health Agency are positives. Overall, the stock price is likely to remain stable, leading to a neutral prediction.
PHGE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
